Gapping up
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- CBK +19.2%, TLYS +18.3%, SMTC +6%, LZB +5.4%, (also increases quarterly dividend by 10% to $0.11 per share), BOX+3.4%, VSM +2.5%
- NWY +1%, DSGX +0.7%, PVH +0.6%
M&A news: CLC +16.3% (to be acquired by Parker Hannifin (PH) for $83.00/share in cash), KZ +2.1% (agrees to be taken private for $7.55/share), SYT +1.8% (Reuters details that ChemChina plans to setup $5 bln fund to finance Syngenta), .
Select EU financial related names showing strength: CS +3.4%, RBS +2.5%, BCS +1.2%, DB +1%
Select oil/gas related names showing early strength:
Select EU financial related names showing strength: CS +3.4%, RBS +2.5%, BCS +1.2%, DB +1%
Select oil/gas related names showing early strength:
- TPLM +10.4%, LEI +9.8%, NAO +8.3%, SDRL +8.2%, WTI +6.5%, MRO +4.9%, CRC +4.6%, OAS +4.5%, CHK +4%,ESV +4%
- BAS +3.9%, REXX +3.7%, RIG +3.6%, RDS.A +1.9%, BP +1.8%
Other news:
- BSTG +27.5% (confirms that its Cellspan Esophageal Implant was granted Orphan Drug Designation by the FDAg)
- BLUE +24% ( announces interim Phase 1 dose escalation data for Anti-BCMA CAR T product candidate in patients with relapsed/refractory multiple myeloma; 100% of patients in second and third dose cohorts achieved objective response; two patients MRD-negative; overall response rate 78%)
- FF +8.6% (declares a special cash dividend of $2.29/share)
- SKX +6.9% (CEO disclosed purchase of 500K shares worth more than $5.5 mln; also upgraded to Buy from Neutral at Buckingham Research)
- CLRB +6.7% (updates on the first two cohorts of its Phase I clinical study of CLR 131)
- CYTK +4.2% (announces that Amgen (AMGN) has started GALACTIC-HF)
- COL +3.5% (Starboard may push for Rockwell to reconsider its pending merger with BEAV)
- JUNO +3.2% (in sympathy with BLUE)
- KITE +3.1% (in sympathy with BLUE)
- PNLYY +2.9% (thinly traded ADR; PostNL acknowledges receipt of revised final proposal from bpost; is reviewing and considering bpost's revised conditional offer)
- MBLY +1.9% (initiated with a Buy at Needham; tgt $55 )
- ZIOP +1.5% (in sympathy with BLUE)
Analyst comments:
- WLL +7.2% (upgraded to Buy from Hold at Stifel)
- SMTC +6.8% (upgraded to Outperform from Perform at Oppenheimer)
- SM +4.3% (upgraded to Buy from Hold at Stifel)
- EOG +2% (upgraded to Buy from Hold at Stifel)
- APC +1.9% (upgraded to Buy from Hold at Stifel)
- DE +1.4% (upgraded to Buy from Neutral at BofA/Merrill)